#1412
MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease
Introduction:
This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).
Conference:
13th Annual ENETSConcerence (2016)
Presenting Author:
Giandomenico V
Authors:
Giandomenico V,
Li S,
Lind T,
Boccherini M,
Skogseid B,
Keywords:
glycolytic metabolism,
peptide receptor radionuclide therapy (PRRT),
serum samples,
miRNA,
FDG-PET positive and-PET negative SI-NET patients,
#503
Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1
Introduction:
The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.
Conference:
9th Annual ENETSConcerence (2012)
Presenting Author:
Authors:
Falkerby J,
Granberg D,
Eriksson B,
Skogseid B,
Öberg K,
Keywords:
neuroendocrine,
Everolimus,
pancreatic,
#196
Efficacy and Safety of the Combination Streptozotocin, 5-FU in Endocrine Pancreatic Tumors: A Retrospective Study
Introduction:
The combination of Streptozotocin with 5-FU has been used during the past decades in our institution as the first-line treatment in pancreatic NETs with low to moderate proliferation.
Conference:
8th Annual ENETSConcerence (2011)
Presenting Author:
Authors:
Antonodimitrakis P,
Skogseid B,
Hurtig M,
Oberg K,
Granberg D,
Keywords:
Streptozotocin,
5-FU,
endocrine pancreatic tumors,
progression-free survival,
side effects,
